Important note

This AI stock analysis for Zimmer Biomet is not up to date. Creating and accessing our AI stock Analysis (powered by our data and Chat GPT) is only available for our premium users. Sign up to get access today!

Zimmer Biomet - AI Stock Analysis

Analysis generated August 31, 2025

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) is a leading medical device company engaged in the design, manufacture, and marketing of orthopedic reconstructive products, sports medicine, biologics, extremities, trauma products, and related surgical products. The company operates in more than 25 countries worldwide and distributes its products in more than 100 countries. Zimmer Biomet has a broad product portfolio and serves a diverse customer base, including orthopedic surgeons, hospitals, and healthcare providers.

Fundamental Analysis

Zimmer Biomet's revenue for the last quarter was $2.08 billion, an increase of 8.81% compared to the previous quarter, which is a positive sign of growth. Year over year, the revenue increased by 6.97%, indicating steady growth in sales. However, the net income for the last quarter was $153 million, which represents a decrease of 16.04% compared to the previous quarter, signaling a potential area of concern. When compared to the same quarter last year, the net income decreased by 37.07%, highlighting significant pressure on profitability.

The EBITDA for the last quarter was $572 million, an increase of 4.11% compared to the previous quarter, which is a sign of improving operating performance. However, EBITDA decreased by 4.07% compared to the same quarter last year, indicating potential challenges in maintaining earnings growth. The current Price-to-Earnings (P/E) ratio stands at 25.88, which may be considered high and suggestive of potential overvaluation, raising a bearish outlook.

Additionally, insider selling has been observed in the last couple of months, which could be viewed as a bearish signal, implying that insiders might expect lower price performance in the near future.

Technical Analysis

Today's stock price of $106.10 represents a 15.77% increase compared to a month ago, indicating a strong short-term bullish trend. However, compared to a year ago, the stock price has decreased by 7.26%, which could raise concerns regarding the long-term outlook. The trend remains bullish overall.

The current Simple Moving Average (SMA10) is $106.81, which is higher than the previous SMA10 of $106.65. This indicates a potential upward trend in price movement. Meanwhile, the Relative Strength Index (RSI) is at 17.7, suggesting oversold conditions and potentially indicating a bullish buying opportunity.

Alternative Data Analysis

Looking at alternative data, Zimmer Biomet has 585 open positions, a 27% increase over the last couple of months. This expansion in hiring indicates that the company is in growth mode, which is generally a healthy sign. The business outlook among employees is neutral.

The company's website traffic has also seen a bullish trend, with an estimated 280,000 visitors, up by 14% in recent months. Increased web traffic can often correlate with an increase in customer acquisition and engagement. On social media, Zimmer Biomet has 12,000 followers on Twitter, with no significant changes in following, indicating stable customer engagement.

According to AltIndex's AI score, which predicts a company's stock price based on fundamental, technical, and alternative data analysis, Zimmer Biomet has an AI score of 44, suggesting a hold signal.

Conclusion and Recommendation

In conclusion, Zimmer Biomet has demonstrated a mixed performance across various metrics. The company has shown solid revenue growth, but declining net income and EBITDA compared to the previous year suggest potential profitability challenges. The technical analysis indicates a short-term bullish trend, but long-term concerns remain due to the higher P/E ratio and insider selling. Alternatives data suggests that Zimmer Biomet is expanding and attracting more interest, but employee sentiment remains neutral.

Given the combination of these factors, the recommendation for Zimmer Biomet based on this analysis is to hold the stock. Investors should continue to monitor the company’s performance, especially its profitability metrics and insider trading activity, to make well-informed decisions.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.